Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians
Therapeutic Advances in Medical Oncology
Published online on June 19, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Extensive stage small cell lung cancer (ES-SCLC) carries a very poor prognosis and has been the focus of intensive research. Targeting cell surface molecules is paying off. Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab ...
Extensive stage small cell lung cancer (ES-SCLC) carries a very poor prognosis and has been the focus of intensive research. Targeting cell surface molecules is paying off. Moving beyond immune checkpoint inhibitors (ICI), targeting DLL3 with tarlatamab ...